• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?

作者信息

Jafar Tazeen H

机构信息

Programme in Health Services and Systems Research, Duke-NUS Medical School, 169857 Singapore; Department of Renal Medicine, Singapore General Hospital, Singapore; Duke Global Health Institute, Duke University, Durham, NC, USA.

出版信息

Lancet. 2021 Jul 24;398(10297):283-284. doi: 10.1016/S0140-6736(21)01242-3. Epub 2021 Jun 4.

DOI:10.1016/S0140-6736(21)01242-3
PMID:34097853
Abstract
摘要

相似文献

1
FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?达格列净获美国食品药品监督管理局批准用于慢性肾病：一项非凡成就？
Lancet. 2021 Jul 24;398(10297):283-284. doi: 10.1016/S0140-6736(21)01242-3. Epub 2021 Jun 4.
2
In brief: Dapagliflozin (Farxiga) for chronic kidney disease.简而言之：达格列净（安达唐）用于慢性肾病。
Med Lett Drugs Ther. 2021 Jul 26;63(1629):115.
3
Oral Empagliflozin Receives FDA Approval for Children With Diabetes.口服恩格列净获美国食品药品监督管理局批准用于儿童糖尿病患者。
JAMA. 2023 Jul 25;330(4):307. doi: 10.1001/jama.2023.12057.
4
A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.钠-葡萄糖协同转运蛋白2抑制剂卡格列净、达格列净和恩格列净的综述
Cardiovasc Hematol Agents Med Chem. 2015;13(2):105-12. doi: 10.2174/1871525714666151106121215.
5
The Authors' Reply to "How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease".作者对《如何证明达格列净对改善慢性肾脏病患者高尿酸血症的影响》的回复
Intern Med. 2024 Aug 1;63(15):2229-2230. doi: 10.2169/internalmedicine.3074-23. Epub 2024 Jan 2.
6
Effect of early treatment with dapagliflozin on the natural history of chronic kidney disease.达格列净早期治疗对慢性肾脏病自然病程的影响。
Nefrologia (Engl Ed). 2024 May-Jun;44(3):435-436. doi: 10.1016/j.nefroe.2023.06.007.
7
Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.达格列净，一种用于治疗2型糖尿病的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂。
Drugs Today (Barc). 2013 May;49(5):289-301. doi: 10.1358/dot.2013.49.5.1964714.
8
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.达格列净对非糖尿病慢性肾脏病患者蛋白尿的影响（DIAMOND）：一项随机、双盲、交叉试验。
Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5.
9
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者尿白蛋白排泄的影响：来自 DAPA-CKD 试验的预设分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4.
10
SGLT2 Inhibitors across the Spectrum of Severity of CKD.SGLT2抑制剂在慢性肾脏病严重程度范围内的应用
Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1386-1388. doi: 10.2215/CJN.13430820. Epub 2020 Sep 29.

引用本文的文献

1
Metabolic-associated enthesitis: a review on pathophysiology, clinical relevance, diagnostic challenges, and perspective on target treatments.代谢相关附着点炎：病理生理学、临床相关性、诊断挑战及靶向治疗前景综述
Immunol Res. 2025 Jul 11;73(1):106. doi: 10.1007/s12026-025-09655-0.
2
Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy.达格列净与吡格列酮联合用药在链脲佐菌素诱导的肾病中并不比单一疗法更具优势。
Sci Rep. 2025 Jan 9;15(1):1464. doi: 10.1038/s41598-024-84487-w.
3
Treatment of Podocytopathies: Risky Business and Our Personal Journey.
足细胞病的治疗：充满风险的事务与我们的个人历程
J Am Soc Nephrol. 2024 Nov 1;35(11):1600-1602. doi: 10.1681/ASN.0000000000000415. Epub 2024 May 15.
4
Discovery and prioritization of genetic determinants of kidney function in 297,355 individuals from Taiwan and Japan.在来自台湾和日本的 297355 个人中发现和优先考虑肾功能的遗传决定因素。
Nat Commun. 2024 Oct 29;15(1):9317. doi: 10.1038/s41467-024-53516-7.
5
Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.达格列净辅助治疗对 2 型糖尿病合并慢性肾脏病 2-5 期患者慢性肾脏病进展的影响：系统评价和荟萃分析。
Sultan Qaboos Univ Med J. 2024 Aug;24(3):317-326. doi: 10.18295/squmj.12.2023.093. Epub 2024 Aug 29.
6
Recent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors.钠-葡萄糖协同转运蛋白1/2抑制剂的最新进展与展望
Mini Rev Med Chem. 2025;25(5):354-364. doi: 10.2174/0113895575325210240805092741.
7
Efficacy and safety of dapagliflozin in children with kidney disease: real-world data.达格列净在儿童肾脏病中的疗效和安全性：真实世界数据。
Pediatr Nephrol. 2024 Dec;39(12):3551-3558. doi: 10.1007/s00467-024-06481-8. Epub 2024 Aug 6.
8
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂用于慢性肾脏病和糖尿病患者。
Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
9
Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease.模拟 SGLT2 抑制在高血压慢性肾病中的肾保护机制。
Physiol Rep. 2023 Nov;11(21):e15836. doi: 10.14814/phy2.15836.
10
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence.钠-葡萄糖协同转运蛋白2抑制剂在非糖尿病慢性肾脏病患者中的疗效与安全性：近期证据综述
Kidney Dis (Basel). 2023 Apr 11;9(5):326-341. doi: 10.1159/000530395. eCollection 2023 Oct.